![Weekly Enforcement Report: All Quiet on the Laboratory Front](https://www.g2intelligence.com/wp-content/uploads/2023/03/Mar1-2023.News_.WeeklyEnforcementReport-NoLabs-iStock-1800x1250-1-1080x675.jpg)
Weekly Enforcement Report: All Quiet on the Laboratory Front
Though labs were again absent from recent key enforcement actions, sentences were handed down in other healthcare-related cases.
Though labs were again absent from recent key enforcement actions, sentences were handed down in other healthcare-related cases.
Though last week’s cases didn’t involve labs or lab testing, most were FCA-related issues including inflated claims.
As we move further into 2023, COVID-19, add-on, and genetic tests will likely remain targets for federal regulators.
A new OIG Advisory Opinion sheds some light on how to properly structure these arrangements in a hospital inpatient setting.
Last week saw the usual False Claims Act and kickback-related charges, with the biggest action involving urine drug testing.